Randomized trial · people

Thymogen (IM862): 36% major responses in AIDS-related Kaposi's sarcoma

Checked against the paper Randomized trialPublished by PepVault

The takeaway

This early human trial links the Glu-Trp dipeptide, given as IM862 nose drops, to tumor responses and mild side effects in AIDS-related Kaposi's sarcoma, but it lacked a placebo comparison, and a later placebo-controlled trial found IM862 no better than placebo.

Kind
Randomized trial
Studied in
People
Published
2000
Journal
J Clin Oncol

What they tested

The team tested whether IM862, a natural peptide the authors describe as blocking new blood vessel growth, given as nose drops, was tolerable and had any effect on Kaposi's sarcoma tied to AIDS.

How the study was done

A randomized phase II trial in adults with AIDS-related Kaposi's sarcoma, almost all of them men, compared two schedules of 5 mg nasal drops: 5 days on and 5 days off (18 patients) or every other day (26 patients), with no placebo group. Treatment ran in cycles until the disease grew or side effects became too much, and 75% had already had chemotherapy.

A woman in glasses at a kitchen table with a laptop, a mug and her phone

PepVault for iPhone

Taking thymogen? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

What they found

Among the patients, 36% had a major response: 5 had a complete remission (tumors cleared) and 11 a partial remission (tumors shrank). Responses showed up after a median of 6 weeks and lasted a median of 33+ weeks, ranging from 12+ to 95+ weeks. Other patients had stable disease for 7 to 72+ weeks. Side effects were mild, short-lived headache, fatigue, tingling and nausea, with no blood-related side effects tied to treatment.

What it doesn’t show

This was a small trial with no placebo or untreated group, so it can't show how much of the effect came from IM862 itself. All but 5 patients were also taking protease inhibitors at the same time. A later, larger placebo-controlled trial of IM862 in the same disease found it no better than placebo.

The paper

Tulpule et al. Results of a randomized study of IM862 nasal solution in the treatment of AIDS-related Kaposi's sarcoma. J Clin Oncol. 2000.

The compound

More studies on Thymogen

Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.

Track it in the app

PepVault for iPhone

Taking thymogen? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo